HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
Dutasteride at 0.5 mg/day does not significantly alter allopregnanolone levels, but higher doses (2.5 mg/day) do. Dutasteride may also have anti-neuroinflammatory effects, but the impact on neurosteroids is still debated.
The user has been treating hair loss with 1mg oral finasteride daily, 1mg topical minoxidil twice daily, and microneedling twice a week. They report improved hair quality and density but are still experiencing shedding.
A user has been on finasteride for 1.5 years and minoxidil for 2 years, experiencing worsening hair shedding, losing 300+ hairs per wash. They are concerned if this indicates the medicine isn't working and are seeking others' experiences.
Hair loss treatments, specifically the use of Finasteride, Nizoral, and dermarolling; potential results from these treatments are discussed, along with potential side effects.